Background/Introduction: data on the efficacy and safety of different antiplatelet regimens are limited in patients with increasing total stent length (TSL).Purpose: to evaluate the impact of the experimental strategy (1-month dual antiplatelet therapy [DAPT] followed by 23-month ticagrelor monotherapy) vs. the reference regimen (12-month DAPT followed by 12-month aspirin monotherapy) in patients with increasing TSL.Methods: the present post-hoc analysis of the Global Leaders trial evaluated the primary endpoint (the composite of the all-cause death and new Q-wave myocardial infarction [MI]) at two years in patients with increasing TSL. In addition, the patient-oriented composite endpoint (POCE) (the composite of all-cause death,...
BACKGROUNDS Data on optimal antiplatelet therapy in patients undergoing stenting of the proximal ...
Aims: The aim of this study was to evaluate the impact of 23-month ticagrelor monotherapy following ...
BACKGROUND The aim of this study was to investigate the impact of ticagrelor monotherapy followin...
AIMS: The aim of this study was to evaluate the impact of a novel antiplatelet regimen in patients w...
AIMS To evaluate the impact of a novel antiplatelet regimen in patients with increasing total ste...
Aims: The aim of this study was to evaluate the impact of a novel antiplatelet regimen in patients w...
Aims: To evaluate the impact of an experimental strategy [23-month ticagrelor monotherapy following ...
AIMS To evaluate the impact of an experimental strategy [23-month ticagrelor monotherapy followi...
Backgrounds: Data on optimal antiplatelet therapy in patients undergoing stenting of the proximal le...
Background: The GLOBAL LEADERS (GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platele...
AIMS: The aim of this study was to evaluate the impact of 23-month ticagrelor monotherapy following ...
BACKGROUND The GLOBAL LEADERS (GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-plate...
Background: The aim of this study was to investigate the impact of ticagrelor monotherapy following ...
BACKGROUND: The optimal duration of dual antiplatelet therapy after coronary drug-eluting stent plac...
International audienceBackground In the GLOBAL LEADERS trial, ticagrelor monotherapy beyond 1 month ...
BACKGROUNDS Data on optimal antiplatelet therapy in patients undergoing stenting of the proximal ...
Aims: The aim of this study was to evaluate the impact of 23-month ticagrelor monotherapy following ...
BACKGROUND The aim of this study was to investigate the impact of ticagrelor monotherapy followin...
AIMS: The aim of this study was to evaluate the impact of a novel antiplatelet regimen in patients w...
AIMS To evaluate the impact of a novel antiplatelet regimen in patients with increasing total ste...
Aims: The aim of this study was to evaluate the impact of a novel antiplatelet regimen in patients w...
Aims: To evaluate the impact of an experimental strategy [23-month ticagrelor monotherapy following ...
AIMS To evaluate the impact of an experimental strategy [23-month ticagrelor monotherapy followi...
Backgrounds: Data on optimal antiplatelet therapy in patients undergoing stenting of the proximal le...
Background: The GLOBAL LEADERS (GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platele...
AIMS: The aim of this study was to evaluate the impact of 23-month ticagrelor monotherapy following ...
BACKGROUND The GLOBAL LEADERS (GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-plate...
Background: The aim of this study was to investigate the impact of ticagrelor monotherapy following ...
BACKGROUND: The optimal duration of dual antiplatelet therapy after coronary drug-eluting stent plac...
International audienceBackground In the GLOBAL LEADERS trial, ticagrelor monotherapy beyond 1 month ...
BACKGROUNDS Data on optimal antiplatelet therapy in patients undergoing stenting of the proximal ...
Aims: The aim of this study was to evaluate the impact of 23-month ticagrelor monotherapy following ...
BACKGROUND The aim of this study was to investigate the impact of ticagrelor monotherapy followin...